'Personalized medicine' to identify genetic risks for type 2 diabetes and focus prevention

Can it fulfill its promise?

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Public health measures are required to address the worldwide increase in type 2 diabetes. Proponents of personalized medicine predict a future in which disease treatment and, more important, prevention will be tailored to high-risk individuals rather than populations and will be based on genetic and other new biomarker tests. Accurate biomarker tests to identify people at risk for diabetes could allow more-targeted and perhaps individualized prevention efforts. DNA variants conferring higher risk for type 2 diabetes have been identified. However, these account for only a small fraction of genetic risk, which limits their practical predictive value. Nor has identification of these variants yet led to new, individualized prevention methods. Further research is needed to identify genomic and other types of biomarkers that could accurately predict risk and facilitate targeted prevention.

Original languageEnglish (US)
Pages (from-to)43-49
Number of pages7
JournalHealth Affairs
Volume31
Issue number1
DOIs
StatePublished - Jan 2012

Fingerprint

Precision Medicine
Type 2 Diabetes Mellitus
Biomarkers
Public Health
DNA
Research
Population

ASJC Scopus subject areas

  • Health Policy

Cite this

@article{8a6f34189a0c48f586a2470881941b72,
title = "'Personalized medicine' to identify genetic risks for type 2 diabetes and focus prevention: Can it fulfill its promise?",
abstract = "Public health measures are required to address the worldwide increase in type 2 diabetes. Proponents of personalized medicine predict a future in which disease treatment and, more important, prevention will be tailored to high-risk individuals rather than populations and will be based on genetic and other new biomarker tests. Accurate biomarker tests to identify people at risk for diabetes could allow more-targeted and perhaps individualized prevention efforts. DNA variants conferring higher risk for type 2 diabetes have been identified. However, these account for only a small fraction of genetic risk, which limits their practical predictive value. Nor has identification of these variants yet led to new, individualized prevention methods. Further research is needed to identify genomic and other types of biomarkers that could accurately predict risk and facilitate targeted prevention.",
author = "Spiegel, {Allen M.} and Hawkins, {Meredith A.}",
year = "2012",
month = "1",
doi = "10.1377/hlthaff.2011.1054",
language = "English (US)",
volume = "31",
pages = "43--49",
journal = "Health Affairs",
issn = "0278-2715",
publisher = "Project Hope",
number = "1",

}

TY - JOUR

T1 - 'Personalized medicine' to identify genetic risks for type 2 diabetes and focus prevention

T2 - Can it fulfill its promise?

AU - Spiegel, Allen M.

AU - Hawkins, Meredith A.

PY - 2012/1

Y1 - 2012/1

N2 - Public health measures are required to address the worldwide increase in type 2 diabetes. Proponents of personalized medicine predict a future in which disease treatment and, more important, prevention will be tailored to high-risk individuals rather than populations and will be based on genetic and other new biomarker tests. Accurate biomarker tests to identify people at risk for diabetes could allow more-targeted and perhaps individualized prevention efforts. DNA variants conferring higher risk for type 2 diabetes have been identified. However, these account for only a small fraction of genetic risk, which limits their practical predictive value. Nor has identification of these variants yet led to new, individualized prevention methods. Further research is needed to identify genomic and other types of biomarkers that could accurately predict risk and facilitate targeted prevention.

AB - Public health measures are required to address the worldwide increase in type 2 diabetes. Proponents of personalized medicine predict a future in which disease treatment and, more important, prevention will be tailored to high-risk individuals rather than populations and will be based on genetic and other new biomarker tests. Accurate biomarker tests to identify people at risk for diabetes could allow more-targeted and perhaps individualized prevention efforts. DNA variants conferring higher risk for type 2 diabetes have been identified. However, these account for only a small fraction of genetic risk, which limits their practical predictive value. Nor has identification of these variants yet led to new, individualized prevention methods. Further research is needed to identify genomic and other types of biomarkers that could accurately predict risk and facilitate targeted prevention.

UR - http://www.scopus.com/inward/record.url?scp=84855687590&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84855687590&partnerID=8YFLogxK

U2 - 10.1377/hlthaff.2011.1054

DO - 10.1377/hlthaff.2011.1054

M3 - Article

VL - 31

SP - 43

EP - 49

JO - Health Affairs

JF - Health Affairs

SN - 0278-2715

IS - 1

ER -